A Phase 3 Randomized double blined placebo controlled study to evaluate the efficacy and safety of GS-5745 conbimed with mFOLFAX6 as first line treatment in patients with advanced gastric or gastroeso
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Gilead Sciences, Inc.
Start Date
March 9, 2016
End Date
June 30, 2020
Administered By
Duke Cancer Institute
Awarded By
Gilead Sciences, Inc.
Start Date
March 9, 2016
End Date
June 30, 2020